Back to news

Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies

PR Newswire•16/11/2026•06:45 ET
1

Key Highlights

  • ➤Medtronic to acquire Contego Medical for $380 million, plus potential post-acquisition payments
  • ➤Contego acquisition includes FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices
  • ➤Medtronic expects transaction completion in fiscal Q3, subject to customary closing conditions
  • ➤Deal minimally dilutive to adjusted EPS in FY27 and FY28, neutral to accretive thereafter
  • ➤Neuroguard IEP Direct System reported zero strokes, neurological deaths, cranial nerve injuries, and myocardial infarctions at 30 days

Expert Statements

David Moeller, Senior vice president and president of Medtronic Peripheral Vascular Health

“With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease”

David Moeller, Senior vice president and president of Medtronic Peripheral Vascular Health

“By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data,(†) we intend to become an undisputed leader in carotid revascularization.”

Ravish Sachar, MD, Founder and Chief Executive Officer of Contego Medical

“Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures. Deepening our partnership with Medtronic is an exciting next chapter”

Ravish Sachar, MD, Founder and Chief Executive Officer of Contego Medical

“We're proud of our team and grateful to the physicians, study sites, employees, and investors who helped bring these technologies to patients.”

Linnea Burman, Senior vice president and president of Medtronic Neurovascular

“Stroke-related disability underscores the need for more innovative treatment options — and the opportunity to make a meaningful difference for patients.”

Linnea Burman, Senior vice president and president of Medtronic Neurovascular

“We are committed to delivering technologies designed to reduce stroke risk and advance patient care. Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease.”

Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies PR Newswire

GALWAY, Ireland, Nov. 16, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), the global leader in healthcare technology, today announced its intent to acquire Contego Medical, a privately held medical device company focused on innovative solutions for carotid artery disease and peripheral thrombectomy.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in